U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Favorable Hodgkin Lymphoma

MedGen UID:
385044
•Concept ID:
C2348517
•
Neoplastic Process

Definition

A Hodgkin lymphoma with favorable prognosis. [from NCI]

Professional guidelines

PubMed

Revisiting the predictive role of 18F-fluorodeoxyglucose positron emission tomography/computerized tomography on treatment outcome in early-stage favorable Hodgkin lymphoma.
Gallamini A, Sudria A, Kurlapski M, Gastaud L
Hematol Oncol 2023 Oct;41(4):608-611. Epub 2023 Apr 20 doi: 10.1002/hon.3158. PMID: 37805963
Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy.
Pinnix CC, Gunther JR, Fang P, Bankston ME, Milgrom SA, Boyce D, Lee HJ, Nair R, Steiner R, Strati P, Ahmed S, Iyer SP, Westin J, Parmar S, Rodriguez MA, Nastoupil L, Neelapu S, Flowers C, Dabaja BS
JAMA Netw Open 2020 Sep 1;3(9):e2013935. doi: 10.1001/jamanetworkopen.2020.13935. PMID: 32990738Free PMC Article
ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II.
Dhakal S, Advani R, Ballas LK, Dabaja BS, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Younes A, Constine LS; Expert Panel on Radiation Oncology–Lymphoma
Am J Clin Oncol 2016 Dec;39(6):535-544. doi: 10.1097/COC.0000000000000331. PMID: 27643717Free PMC Article

Recent clinical studies

Etiology

Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.
Fuchs M, Jacob AS, Kaul H, Kobe C, Kuhnert G, Pabst T, Greil R, Bröckelmann PJ, Topp MS, Just M, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Dührsen U, Meissner J, Viardot A, Eich HT, Baues C, Diehl V, Rosenwald A, Buehnen I, von Tresckow B, Dietlein M, Borchmann P, Engert A, Eichenauer DA
Leukemia 2024 Jan;38(1):160-167. Epub 2023 Oct 16 doi: 10.1038/s41375-023-02064-y. PMID: 37845285Free PMC Article
Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial.
van Heek L, Stuka C, Kaul H, Müller H, Mettler J, Hitz F, Baues C, Fuchs M, Borchmann P, Engert A, Dietlein M, Voltin CA, Kobe C
BMC Cancer 2022 Jun 18;22(1):672. doi: 10.1186/s12885-022-09758-z. PMID: 35717166Free PMC Article
Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy.
Bröckelmann PJ, Müller H, Guhl T, Behringer K, Fuchs M, Moccia AA, Rank A, Soekler M, Vieler T, Pabst T, Baues C, von Tresckow B, Borchmann P, Engert A
J Clin Oncol 2021 Jan 10;39(2):107-115. Epub 2020 Oct 15 doi: 10.1200/JCO.20.00947. PMID: 33058716
Radiation Dose Reduction in Early-Stage Hodgkin Lymphoma.
Shah BA, Oh C, Wu SP, Karp JM, Grossbard M, Gerber NK
Clin Lymphoma Myeloma Leuk 2020 Dec;20(12):820-829. Epub 2020 Jul 22 doi: 10.1016/j.clml.2020.07.010. PMID: 32800712
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, Sasse S, Topp MS, Schäfer E, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Wilhelm M, Maschmeyer G, Thiemer J, Dührsen U, Meissner J, Viardot A, Eich H, Baues C, Diehl V, Rosenwald A, von Tresckow B, Dietlein M, Borchmann P, Engert A
J Clin Oncol 2019 Nov 1;37(31):2835-2845. Epub 2019 Sep 10 doi: 10.1200/JCO.19.00964. PMID: 31498753

Diagnosis

Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.
Fuchs M, Jacob AS, Kaul H, Kobe C, Kuhnert G, Pabst T, Greil R, Bröckelmann PJ, Topp MS, Just M, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Dührsen U, Meissner J, Viardot A, Eich HT, Baues C, Diehl V, Rosenwald A, Buehnen I, von Tresckow B, Dietlein M, Borchmann P, Engert A, Eichenauer DA
Leukemia 2024 Jan;38(1):160-167. Epub 2023 Oct 16 doi: 10.1038/s41375-023-02064-y. PMID: 37845285Free PMC Article
Is Radiation Therapy Cost-Effective in the Positron Emission Tomography/Computed Tomography Era for Early-Stage Favorable Hodgkin Lymphoma With Alternative Payment Models?
Kim H, Richman A, Smith KJ, Shaikh PM, Beriwal S, Vargo JA
Pract Radiat Oncol 2022 Mar-Apr;12(2):e135-e143. Epub 2021 Dec 11 doi: 10.1016/j.prro.2021.11.010. PMID: 34902637
Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy.
Bröckelmann PJ, Müller H, Guhl T, Behringer K, Fuchs M, Moccia AA, Rank A, Soekler M, Vieler T, Pabst T, Baues C, von Tresckow B, Borchmann P, Engert A
J Clin Oncol 2021 Jan 10;39(2):107-115. Epub 2020 Oct 15 doi: 10.1200/JCO.20.00947. PMID: 33058716
Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy.
Pinnix CC, Gunther JR, Fang P, Bankston ME, Milgrom SA, Boyce D, Lee HJ, Nair R, Steiner R, Strati P, Ahmed S, Iyer SP, Westin J, Parmar S, Rodriguez MA, Nastoupil L, Neelapu S, Flowers C, Dabaja BS
JAMA Netw Open 2020 Sep 1;3(9):e2013935. doi: 10.1001/jamanetworkopen.2020.13935. PMID: 32990738Free PMC Article
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, Sasse S, Topp MS, Schäfer E, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Wilhelm M, Maschmeyer G, Thiemer J, Dührsen U, Meissner J, Viardot A, Eich H, Baues C, Diehl V, Rosenwald A, von Tresckow B, Dietlein M, Borchmann P, Engert A
J Clin Oncol 2019 Nov 1;37(31):2835-2845. Epub 2019 Sep 10 doi: 10.1200/JCO.19.00964. PMID: 31498753

Therapy

Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.
Fuchs M, Jacob AS, Kaul H, Kobe C, Kuhnert G, Pabst T, Greil R, Bröckelmann PJ, Topp MS, Just M, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Dührsen U, Meissner J, Viardot A, Eich HT, Baues C, Diehl V, Rosenwald A, Buehnen I, von Tresckow B, Dietlein M, Borchmann P, Engert A, Eichenauer DA
Leukemia 2024 Jan;38(1):160-167. Epub 2023 Oct 16 doi: 10.1038/s41375-023-02064-y. PMID: 37845285Free PMC Article
Is Radiation Therapy Cost-Effective in the Positron Emission Tomography/Computed Tomography Era for Early-Stage Favorable Hodgkin Lymphoma With Alternative Payment Models?
Kim H, Richman A, Smith KJ, Shaikh PM, Beriwal S, Vargo JA
Pract Radiat Oncol 2022 Mar-Apr;12(2):e135-e143. Epub 2021 Dec 11 doi: 10.1016/j.prro.2021.11.010. PMID: 34902637
Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy.
Bröckelmann PJ, Müller H, Guhl T, Behringer K, Fuchs M, Moccia AA, Rank A, Soekler M, Vieler T, Pabst T, Baues C, von Tresckow B, Borchmann P, Engert A
J Clin Oncol 2021 Jan 10;39(2):107-115. Epub 2020 Oct 15 doi: 10.1200/JCO.20.00947. PMID: 33058716
Radiation Dose Reduction in Early-Stage Hodgkin Lymphoma.
Shah BA, Oh C, Wu SP, Karp JM, Grossbard M, Gerber NK
Clin Lymphoma Myeloma Leuk 2020 Dec;20(12):820-829. Epub 2020 Jul 22 doi: 10.1016/j.clml.2020.07.010. PMID: 32800712
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, Sasse S, Topp MS, Schäfer E, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Wilhelm M, Maschmeyer G, Thiemer J, Dührsen U, Meissner J, Viardot A, Eich H, Baues C, Diehl V, Rosenwald A, von Tresckow B, Dietlein M, Borchmann P, Engert A
J Clin Oncol 2019 Nov 1;37(31):2835-2845. Epub 2019 Sep 10 doi: 10.1200/JCO.19.00964. PMID: 31498753

Prognosis

Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.
Fuchs M, Jacob AS, Kaul H, Kobe C, Kuhnert G, Pabst T, Greil R, Bröckelmann PJ, Topp MS, Just M, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Dührsen U, Meissner J, Viardot A, Eich HT, Baues C, Diehl V, Rosenwald A, Buehnen I, von Tresckow B, Dietlein M, Borchmann P, Engert A, Eichenauer DA
Leukemia 2024 Jan;38(1):160-167. Epub 2023 Oct 16 doi: 10.1038/s41375-023-02064-y. PMID: 37845285Free PMC Article
Revisiting the predictive role of 18F-fluorodeoxyglucose positron emission tomography/computerized tomography on treatment outcome in early-stage favorable Hodgkin lymphoma.
Gallamini A, Sudria A, Kurlapski M, Gastaud L
Hematol Oncol 2023 Oct;41(4):608-611. Epub 2023 Apr 20 doi: 10.1002/hon.3158. PMID: 37805963
Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial.
van Heek L, Stuka C, Kaul H, Müller H, Mettler J, Hitz F, Baues C, Fuchs M, Borchmann P, Engert A, Dietlein M, Voltin CA, Kobe C
BMC Cancer 2022 Jun 18;22(1):672. doi: 10.1186/s12885-022-09758-z. PMID: 35717166Free PMC Article
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, Sasse S, Topp MS, Schäfer E, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Wilhelm M, Maschmeyer G, Thiemer J, Dührsen U, Meissner J, Viardot A, Eich H, Baues C, Diehl V, Rosenwald A, von Tresckow B, Dietlein M, Borchmann P, Engert A
J Clin Oncol 2019 Nov 1;37(31):2835-2845. Epub 2019 Sep 10 doi: 10.1200/JCO.19.00964. PMID: 31498753

Clinical prediction guides

Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.
Fuchs M, Jacob AS, Kaul H, Kobe C, Kuhnert G, Pabst T, Greil R, Bröckelmann PJ, Topp MS, Just M, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Dührsen U, Meissner J, Viardot A, Eich HT, Baues C, Diehl V, Rosenwald A, Buehnen I, von Tresckow B, Dietlein M, Borchmann P, Engert A, Eichenauer DA
Leukemia 2024 Jan;38(1):160-167. Epub 2023 Oct 16 doi: 10.1038/s41375-023-02064-y. PMID: 37845285Free PMC Article
Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial.
van Heek L, Stuka C, Kaul H, Müller H, Mettler J, Hitz F, Baues C, Fuchs M, Borchmann P, Engert A, Dietlein M, Voltin CA, Kobe C
BMC Cancer 2022 Jun 18;22(1):672. doi: 10.1186/s12885-022-09758-z. PMID: 35717166Free PMC Article
Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy.
Bröckelmann PJ, Müller H, Guhl T, Behringer K, Fuchs M, Moccia AA, Rank A, Soekler M, Vieler T, Pabst T, Baues C, von Tresckow B, Borchmann P, Engert A
J Clin Oncol 2021 Jan 10;39(2):107-115. Epub 2020 Oct 15 doi: 10.1200/JCO.20.00947. PMID: 33058716
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, Sasse S, Topp MS, Schäfer E, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Wilhelm M, Maschmeyer G, Thiemer J, Dührsen U, Meissner J, Viardot A, Eich H, Baues C, Diehl V, Rosenwald A, von Tresckow B, Dietlein M, Borchmann P, Engert A
J Clin Oncol 2019 Nov 1;37(31):2835-2845. Epub 2019 Sep 10 doi: 10.1200/JCO.19.00964. PMID: 31498753
Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD × two cycles followed by FDG-PET/CT restaging and 20 Gy of involved-site radiotherapy.
Kamran SC, Jacene HA, Chen YH, Mauch PM, Ng AK
Leuk Lymphoma 2018 Jun;59(6):1384-1390. Epub 2017 Sep 22 doi: 10.1080/10428194.2017.1376745. PMID: 28937297

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...